Friday, 29th May 2026

News published by QIMR Berghofer revealed the first major analysis from the Australian Parkinson’s Genetics Study (APGS)has uncovered substantial differences in how Parkinson’s disease manifests and progresses in men and women, highlighting the need for more personalised approaches to prevention, diagnosis and care.
Nearly 11,000 people with Parkinson’s disease participated in the Australian Parkinson’s Genetics Study, which involved answering a wide-ranging questionnaire on their experience with the condition, and supplying a saliva sample.
The study found:
“These differences tell us that Parkinson’s is not a one-size-fits-all disease,” said Associate Professor Miguel Rentería, who heads up the Computational Neurogenomics Laboratory at QIMR Berghofer. “The distinct patterns we see in men and women may reflect different underlying biological pathways and environmental exposures. Understanding these differences is essential if we want to move towards truly personalised approaches to prevention, diagnosis, and treatment.”
The Australian Parkinson’s Genetics Study found that environmental exposures prior to diagnosis also differed markedly between the sexes.
Whilst the researchers note it’s not known yet whether environmental exposure alone can cause Parkinson’s disease, the results confirm that certain exposures are more common among people with the condition.
PhD candidate Fangyuan (Elainor) Cao, who led the analysis at QIMR Berghofer, says the scale and depth of the dataset lays the groundwork for Parkinson’s disease breakthroughs.
“What struck me most was just how varied the experience of Parkinson’s is – not only between individuals, but between men and women. The richness of this dataset allows us to move beyond averages and start to understand why the disease looks so different from one person to the next.”
Clinician and researcher Associate Professor Kishore Kumar believes the work will help inform and educate doctors about the vastly different ways Parkinson’s disease can present.
“This cohort is a remarkable national resource that will drive future genetic and longitudinal research and, ultimately, help improve the lives of people living with Parkinson’s.”
Shake It Up Australia, in partnership with the Michael J. Fox Foundation, has supported the expansion of the APGS. CEO Vicki Miller said the findings reinforce the importance of supporting this type of research here in Australia.
“Shake It Up Australia has proudly supported the APGS since 2022 because we believe large-scale Australian research is essential to finding better treatments and, ultimately, a cure. Seeing this study grow to become the largest active Parkinson’s cohort in the world is extraordinary, and it’s a testament to the generosity of the thousands of Australians who gave their time to participate. This is exactly the kind of bold, ambitious research our community needs.”